Advanced Oncotherapy PLC represents a commitment to innovation, excellence, and patient-centric care in the field of advanced cancer treatment solutions. With a strong focus on delivering cutting-edge proton beam therapy technology, the company aims to revolutionize cancer treatment and enhance patient outcomes. Advanced Oncotherapy PLC is dedicated to providing personalized, precise, and cost-effective therapies to cancer patients worldwide. Its corporate philosophy revolves around advancing the field of oncology through research, collaboration, and continuous improvement. By harnessing state-of-the-art technology and prioritizing patient well-being, Advanced Oncotherapy PLC strives to make a meaningful difference in the fight against cancer.

Advanced Oncotherapy PLC is primarily present in the United Kingdom.

Advanced Oncotherapy PLC has achieved several significant milestones. One notable achievement is the successful completion of the first LIGHT system installation at a proton therapy center in Harley Street, London. Additionally, the company has made progress in securing partnerships and collaborations with recognized industry leaders. Advanced Oncotherapy PLC has also demonstrated its commitment to innovation by obtaining regulatory clearances and patents for its cutting-edge technologies. Furthermore, the company continues to advance its research and development efforts, aiming to provide effective and affordable cancer treatment solutions to patients worldwide.

Advanced Oncotherapy PLC is a leading company in the field of proton therapy technology. Established in 2006, the company is dedicated to advancing cancer treatment by developing and commercializing innovative proton therapy systems. Advanced Oncotherapy PLC aims to make proton therapy more accessible and affordable through its cutting-edge LIGHT system. This system leverages revolutionary technology, optimizing cancer treatment with precise doses of proton beams. The team behind Advanced Oncotherapy PLC consists of experienced professionals, including scientists and engineers, who are committed to making a significant impact on cancer care. With a strong focus on research and development, the company is poised to revolutionize cancer treatment worldwide.

The main competitors of Advanced Oncotherapy PLC in the market include Varian Medical Systems, Elekta AB, and Accuray Incorporated.

Advanced Oncotherapy PLC is primarily active in the healthcare industry. With a focus on innovative and advanced technologies, the company offers solutions for the treatment of cancer. Advanced Oncotherapy PLC develops and manufactures state-of-the-art proton therapy systems that aim to provide more precise and effective cancer treatments. By leveraging cutting-edge medical technology, the company strives to contribute to the advancement of cancer care and improve patient outcomes. With its presence in the healthcare sector, Advanced Oncotherapy PLC plays a significant role in addressing the critical needs of cancer patients and medical professionals.

The business model of Advanced Oncotherapy PLC focuses on developing and providing advanced technologies and innovative solutions for the treatment of cancer. The company specializes in the design, development, and commercialization of proton therapy systems, which enable precise and targeted radiation therapy. Advanced Oncotherapy PLC aims to revolutionize cancer treatment by offering cost-effective and compact proton beam therapy systems that are suitable for both large academic centers and private clinics. By harnessing the power of proton therapy, the company aims to improve patient outcomes while reducing the side effects typically associated with traditional radiation therapy methods.

Rasio P/E Advanced Oncotherapy adalah -0,01.

Rasio KUV dari Advanced Oncotherapy adalah 0,00.

Skor Kualitas AlleAktien untuk Advanced Oncotherapy adalah 3/10.

Omset diharapkan Advanced Oncotherapy adalah 103,31 Juta. GBP.

Laba diharapkan Advanced Oncotherapy adalah -8,94 Juta. GBP.

Advanced Oncotherapy is a medical company specializing in the development and manufacturing of advanced technologies for cancer treatment. Their business model includes technology development as well as providing services and products. The main product is the LIGHT (Linac Image Guided Hadron Technology) radiotherapy platform, which allows for precise targeted treatment of tumors in inaccessible areas of the body or near sensitive tissues using a combination of linear accelerator and hadron technology. They also offer services and products such as biopsy solutions and custom imaging solutions tailored to the specific needs of their customers. Additionally, they invest in research and development and collaborate with research institutions and universities. Their goal is to market and sell their technology globally by collaborating with distributors and governments to integrate their products into healthcare systems worldwide. Advanced Oncotherapy aims to continually innovate and provide better solutions for their customers, positioning them for future growth and success in the cancer treatment market.

Advanced Oncotherapy membayarkan dividen sebesar 0 GBP yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Advanced Oncotherapy saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Advanced Oncotherapy adalah GB00BD6SX109.

WKN dari Advanced Oncotherapy adalah A2AL9X.

Ticker dari Advanced Oncotherapy adalah AVO.L.

Dalam 12 bulan terakhir, Advanced Oncotherapy membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Advanced Oncotherapy diperkirakan akan membayar dividen sebesar 0 GBP.

Imbal hasil dividen dari Advanced Oncotherapy saat ini adalah .

Advanced Oncotherapy membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Advanced Oncotherapy membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 GBP. Ini setara dengan yield dividen sebesar 0 %.

Advanced Oncotherapy dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Advanced Oncotherapy tanggal 9/11/2024 sejumlah 0 GBP, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 9/11/2024.

Pembayaran dividen terakhir dilakukan pada 9/11/2024.

Pada tahun 2023, Advanced Oncotherapy 0 GBP telah dibayarkan sebagai dividen.

Dividen dari Advanced Oncotherapy dibayarkan dalam GBP.